Inozyme Pharma, Inc. (INZY)
| Market Cap | 309.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.80M |
| Shares Out | 23.66M |
| EPS (ttm) | -2.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,893 |
| Open | 13.10 |
| Previous Close | 13.36 |
| Day's Range | 12.35 - 13.91 |
| 52-Week Range | 11.12 - 29.46 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 36.00 (+174.8%) |
| Est. Earnings Date | Nov 11, 2021 |
About INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquarter...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Inozyme Pharma stock is "Strong Buy." The 12-month stock price forecast is 36.00, which is an increase of 174.81% from the latest price.
News
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mi...
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency –
Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today ...
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of A...
INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency INZ-701 was previously granted Orphan Drug Designation ...
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today ...
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ...
- Clinical trial initiation expected in mid-2021 – - Preliminary safety and biomarker data expected by the end of 2021 -
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights
– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 –
Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency
Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in ...
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency
- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model -
Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ...
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disord...
Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at t...
- Study results underscore high and shifting disease impacts across age groups, reflecting evolution of disease symptomology - - Study results underscore high and shifting disease impacts across age gro...
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mi...
Inozyme Pharma Expands its Scientific Advisory Board
- Appoints veteran leaders with deep scientific and clinical expertise in vascular calcification, renal disease, and diseases with neointimal proliferation - - Appoints veteran leaders with deep scienti...
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights
– Received Orphan Drug Designation by the U.S. Food and Drug Administration for INZ-701 for treatment of ABCC6 deficiency –
The Balancing Act® on Lifetime to Feature ENPP1 Deficiency
Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal min...
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the T...
– U.S. Food and Drug Administration cleared Investigational New Drug Application –
Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –
Inozyme Pharma Appoints Kevin B. Johnson, Ph.D.
Dr. Johnson Brings More Than 25 Years of Experience in Developing and Implementing Global Regulatory and Clinical Development Strategies from Preclinical Through Product Approval Dr. Johnson Brings More...
Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer
– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs –
Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights
Upsized IPO in July 2020 raised $128.8 million in gross proceeds